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Abstract: The transfer of adenosine diphosphate (ADP)-ribose unit(s) from nicotinamide adenine
dinucleotide (NAD+) to acceptor proteins is known as ADP-ribosylation. This post-translational
modification (PTM) unavoidably alters protein functions and signaling networks, thereby impacting
cell behaviors and tissue outcomes. As a ubiquitous mechanism, ADP-ribosylation affects multiple
tissues, including bones, as abnormal ADP-ribosylation compromises bone development and
remodeling. In this review, we describe the effects of ADP-ribosylation in bone development
and maintenance, and highlight the underlying mechanisms.
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1. Introduction
Adenosine diphosphate (ADP)-ribosylation is the transfer of ADP-ribose units from nicotinamide
adenine dinucleotide (NAD+) to acceptor proteins [1,2]. This post-translational modification
(PTM) either occurs as mono-ADP-ribosylation (MARylation) or poly-ADP-ribosylation (PARylation)
upon attachment of a single or up to 200 ADP-riboses to targeted proteins, respectively [1–6].
ADP-ribosylation is catalyzed by ADP-ribosyltransferases (ARTs), which include diphtheria toxin-like
ARTs (ARTDs), also known as poly(ADP-ribose) polymerases (PARPs), and cholera toxin-like ARTs
(ARTCs), and some sirtuins (SIRTs) [1,2]. The human genome encodes 17 ARTDs, 4 ARTCs, and 7
SIRT members [1,2,7]. While PARylation, which can be linear or branched, is carried out by ART
family members such as ARTD1, ARTD2, ARTD5, and ARTD6, MARylation is the function of a subset
of ARTDs (e.g., ARTD3, ARDT10, and ARTD14), ARTCs (ARTC1 and ARTC5), and SIRTs (SIRT4
and SIRT6) [1,2,7,8]. ADP-ribosylation is reversible, as ADP-riboses are removed from MARylated
proteins by enzymes such as ADP-ribosyl hydrolases (ARH1 and ARH3), terminal ADP-ribose protein
glycohydrolase 1 (TARG1), macrodomains (MacroD1 and MacroD2), and from PARylated proteins
by ARH3 and poly(ADP-ribose) glycohydrolase (PARG) [2,8,9]. By modifying or regulating proteins
endowed with structural roles (e.g., histones), signaling functions, (e.g., mitogen-activated protein
kinases, MAPKs), or transcriptional activities (e.g., transcription factors) [10–14], ARTs profoundly
influence the whole organism homeostasis through regulation of countless cellular events, including
transcription, replication, proliferation, differentiation, and survival [13,15–17]. Structural homologies,
activity specificities, and cellular distributions of ARTs, as well as non-skeletal pathologies caused by
these proteins, have been comprehensively reviewed elsewhere [1,2,4,16,18,19], therefore, this review
does not discuss these topics, but focuses on bone regulation by ADP-ribosylation.
During development, mesenchymal condensations ossify directly or indirectly via a cartilaginous
template, embryonic events known as intramembranous and endochondral ossification, respectively,
where bone formation by the osteoblasts dominates bone resorption by the osteoclasts [20–22].
Postnatally, particularly during adulthood, bone resorption is offset by bone formation, a coupling
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process that preserves bone mass and biomechanical properties (Figure 1). An imbalance between bone
resorption and formation underlies a variety of diseases featured by excessive bone gain or loss [23–25].
While the osteoclasts arise from hematopoietic stem cells, the osteoblasts derive from mesenchymal
stem cells (MSCs), which can also differentiate into adipocytes and chondrocytes under the influence
of specific environmental cues [26,27], as detailed below. Excessive bone marrow adipogenesis at the
expenses of osteogenesis has deleterious effects on bone, a tissue in which various cell types, including
mesenchymal and hematopoietic cells, express a repertoire of ARTs and SIRTs. We review the impact
of ADP-ribosylation on the differentiation of the osteoclasts, osteoblasts, and adipocytes, focusing on
ART and SIRT members with a functional link to bone health and disease.
Figure 1. Bone remodeling. In adults, the osteoclasts (OCs) and other hematopoietic lineages (not
depicted) arise from bone marrow hematopoietic stem cells (HSCs); the osteoblasts differentiate from
mesenchymal stem cells (MSCs), which can also develop into adipocytes and other lineages (not
depicted). Dashed and gray arrows indicate bidirectional regulatory interactions and coupling between
bone resorption and formation, respectively.
2. Osteoclast Differentiation
During development, the emerging ossification centers recruit myeloid progenitors where
they undergo terminal differentiation into the osteoclasts, which resorb the mineralized matrix, an
action that over time results in the formation of the bone marrow cavity [28–30]. Postnatally, the
damaged or old bone matrix is sensed and removed by the osteoclasts, and is evenly replaced by
the osteoblasts. Potential sensors of defective bone matrix components include the innate immune
complex, NOD-like receptor family (NLR), pyrin domain containing 3 (NLRP3) inflammasome,
which is activated by bone matrix degradation products and promotes osteoclast differentiation [31,
32]. While bone marrow myeloid precursors (e.g., CD11blowCD115highCD117high-expressing cells)
differentiate into the osteoclasts in homeostatic conditions, circulating monocytes are capable of
forming osteoclasts or fusing with pre-existing multinucleated osteoclasts in pathological settings,
such as inflammatory arthritis [33–38]. Osteoclast differentiation, activity, and survival depend on
macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL),
whose expression and signaling outputs are regulated by various factors such as hormones (e.g.,
parathyroid hormone, estrogen, and 1,25α-dihydroxyvitamin D3) and pro-inflammatory cytokines,
including those of the tumor necrosis factor (TNF) and interleukin-1 (IL-1) families [23–25,39]. For
simplicity, this review focuses on osteoclast differentiation, though other biological aspects of these
cells, such as activity and survival, are occasionally described. M-CSF, RANKL, and the majority of
osteoclast-regulating factors are mainly produced by cells of the osteoblast lineage, and immune cells
(e.g., macrophages, T and B lymphocytes) though the osteoclasts themselves produce factors such as
sphingosine-1-phosphate and Wnts, which act not only in autocrine manner, but also paracrine fashion,
regulating the functions of neighboring cells such as the osteoblasts [40–45]. Osteoclast differentiation
is driven by complex interactions among various transcription factors, including the nuclear factor of
activated T cells cytoplasmic 1 (NFATc1), NF-κB, and c-Fos [46]. While the effects of PTMs such as
phosphorylation, methylation, ubiquitination, and SUMOylation on transcriptional regulation and
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other key osteoclastogenic events have been extensively studied [47–55], only a few studies have
investigated the role of ADP-ribosylation in osteoclast biology.
2.1. Role of ARTD1 in Osteoclast Differentiation
ARTD1 is the most studied member of the ARTD family in the skeleton. Early studies show that
ARTD1 protein levels decline during in vitro osteoclast differentiation induced by RANKL, a response
that correlates with increased expression of the a3 isoform of the V-ATPase subunit, tartrate-resistant
acid phosphatase, and brain-type creatine kinase [56–59]. In agreement with the proposition that
ARTD1 is a negative regulator of osteoclastogenesis, this protein binds to and represses the activity of
the promoters of the aforementioned genes in the osteoclast precursors [56–59]. Follow up studies
using engineered mice expressing uncleavable ARTD1 or Artd1-deficient mice, not only reinforce the
anti-osteoclastogenic functions of ARTD1, but also shed light into the underlying mechanisms [60–63].
Novel insights include the demonstration that i) ARTD1 inhibits histone3lysine4 trimethylation
(H3K4me3), histone marks of active chromatin, at the promoters of key osteoclastogenic factors such as
B lymphocyte-induced maturation protein 1 (Blimp1), and ii) ARTD1 PARylates itself during osteoclast
formation, a prerequisite modification that targets this protein for destruction through the proteasome
pathway [63]. ARTD1 also inhibits H3K4me3 and H4 acetylation, thereby impeding the recruitment
of the RelA subunit of NF-κB to the IL-1β promoter [61]. Progressive decline in ARTD1 levels also
occurs during the differentiation of myotubes, which are multinucleated fibers that arise from the
fusion of myoblasts [64]. The basis for the apparent inverse correlation between ARTD1 abundance
and multinucleation is unclear, though it is tempting to speculate that the degradation of this enzyme,
whose activity can deplete total intracellular NAD+ levels by 80% may be necessary to prevent energy
collapse during the high energy-demanding differentiation process.
Mice lacking ARTD1 globally or selectively in myeloid cells indistinguishably exhibit a low bone
mass phenotype associated with an increased number of the osteoclasts on bone surfaces (Wang et al.,
personal communication). Consistent with the view of osteoclast lineage autonomous actions of
ARTD1, in vitro osteoclastogenesis from isolated mouse bone marrow cells is higher in Artd1 null
cells compared to wild-type controls [61]. Potential ARTD1 substrates include the master regulators
of osteoclast differentiation, NF-κB and NFATc1, which are PARylated by this enzyme in T cells and
smooth muscle cells [65–69]. However, such interplay is unlikely in light of the recent study indicating
that PARylated NF-κB and NFATc1 are undetectable in cells of the osteoclast lineage. Instead, ARTD1
consistently PARylates histone H2B among other proteins, and decreases the occupancy of H2B at
the NFATc1 promoter, thereby inhibiting NFATc1 expression and restraining osteoclast differentiation
(Wang et al., personal communication).
ARTD1 is cleaved at D214 into 89 kDa and 24 kDa fragments, presumably by caspase-7, in response
to activation of the NLRP3 and NLR, CARD containing 4 (NLRC4) inflammasomes [63,70–72].
Consistent with its pro-inflammatory actions, loss of ARTD1 partially protects joints from destruction
in the mouse model of collagen antibody-induced arthritis [73–77]. In line with the ability of ARTD1
and its cleaved fragments to activate signaling platforms such as the NF-κB pathway, knockin mice
expressing uncleavable ARTD1 are resistant to ischemia/reperfusion-induced inflammation in intestine
and kidney [60,65]. Unexpectedly, this ARTD1 mutant does not affect inflammatory outcomes induced
by hyperactive NLRP3 inflammasome [62]. These conflicting results may be explained by the fact that
ARTD1 actions are cell-context-dependent. Indeed, ARTD1 promotes NF-κB PARylation or activity
in cultured smooth muscle cells, neuronal cells, and macrophages, while negatively regulating this
transcription factor in lymphocytic leukemia cells [65,66,68,72]. Despite some gaps in our understanding
of ARTD1 mechanisms of action, evidence overwhelmingly indicates that this enzyme negatively
regulates osteoclast development (Figure 2).
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Figure 2. Effects of ADP-ribosylation on osteoclast formation. ARTD1, ARTD5, and ARTD6 catalyze the
attachment of ADP-ribose polymers from NAD+ to target proteins (PARylation), releasing nicotinamide
(NAM) in the process; their actions lead to the inhibition of osteoclast differentiation. SIRT6 inhibits
osteoclast development; however, the effects of its MARylating actions in this process are not clear
because this enzyme also has deacetylase activity. Lysine deacetylation is coupled to NAD+ hydrolysis,
yielding a deacetylated targeted protein, O-acetyl-ADP-ribose, and NAM. Ac, acetyl.
2.2. Role of ARTD5 and ARTD6 in Osteoclast Differentiation
ARTD5 (also known as PARP5A or tankyrase 1) and ARTD6 (also referred to as PARP5B or
tankyrase 2) [8] are expressed by many cell types, including the osteoclast lineage [78–81]. ARTD5 and
ARTD6 are implicated in a range of biological processes, including DNA repair, glucose homeostasis
and energy expenditure, and skeletal metabolism (through their interactions with the adaptor protein
SH3 domain-binding protein 2, SH3BP2 and AXIN 1/2) [78,82–86]. PARylation targets SH3BP2 for
ubiquitination by the E3-ubiquitin ligase RNF46, and subsequently for degradation [78,87]. Missense
mutations in SH3BP2 result in SH3BP2 that is stable, as it escapes the destructive actions of ARTD5 and
ARTD6, and are associated with cherubism, a hereditary childhood-onset autoinflammatory disorder,
whose severity regresses after puberty [88]. Focal facial bone lesions and deformities associated with the
destruction of the jaws and dental complications characterize this disease [88]. Knockin mice expressing
the most common disease-associated allele develop systemic inflammation (e.g., excessive TNF-α
production) and bone loss due to massive osteoclast differentiation as a consequence of heightened
sensitivity to M-CSF- and RANKL-induced signals; these events ultimately cumulate in hyperactivation
of osteoclastogenic pathways such as Src, Syk, ERK1/2, and NFATc1 [78,79]. Conversely, Sh3bp2-deficient
osteoclasts exhibit defective bone resorption in vitro [80]. Furthermore, pharmacological inhibition
of ARTD5 and ARTD6, which results in SH3BP2 accumulation, promotes osteoclast differentiation
in vitro and bone resorption in vivo [81,89], findings that are consistent with accelerated in vitro
osteoclastogenesis of osteoclast precursors lacking both ARTD5 and ARTD6 [78]. A recent study
suggests that oral bacteria produce pathogen-associated molecular patterns (PAMPs), which in
conjunction with danger-associated molecular patterns (DAMPs) released during the remodeling of
the jaws, provide tissue-restricted bone lesions in cherubism. Decreased jaw remodeling with age
leading to attenuated levels of DAMPs may underlie the reported regression of this disorder over time
in the affected patients [90]. Thus, ARTD5 and ARTD6 function as negative regulators of osteoclast
differentiation (Figure 2).
2.3. Role of SIRT6 in Osteoclast Differentiation
SIRTs are involved in the regulation of insulin secretion, gluconeogenesis, transcriptional regulation,
and several other biological responses [91–95]. Relevant to this review are SIRT4 and SIRT6, owing
to their MARylation activity that targets numerous proteins including glutamate dehydrogenase
and ARTD1 [91,96–98]. SIRT6 also MARylates itself, a presumed mechanism of self-regulation [99].
Notably, SIRT6, but not SIRT4, has a strong deacetylase activity, a reaction where lysine deacetylation is
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coupled to NAD+ hydrolysis yielding O-acetyl-ADP-ribose, nicotinamide, and a deacetylated targeted
protein [100–103].
Consistent with SIRT6 inhibitory effects on the transactivation of NF-κB, an important regulator of
osteoclast development, overexpression of SIRT6 suppresses RANKL-induced OC formation in vitro
and bone destruction in mice with collagen-induced arthritis [25,104–106]. Conversely, SIRT6 deficiency
causes premature aging associated with increased osteoclastogenesis and low bone mass, or osteopenia
associated with low bone turnover [107–110]. Moreover, myeloid-specific deletion of SIRT6 results in a
decrease in estrogen receptor α protein levels and apoptosis of pre-osteoclasts, resulting in massive
bone resorption during aging and following ovariectomy [111]. Accordingly, SIRT6 transgenic mice
are protected from ovariectomy-induced bone loss. Mechanistically, SIRT6 deacetylates estrogen
receptor α at K171 and K299, thereby preventing its proteasomal degradation. In contrast to these
studies, SIRT6 reportedly forms a complex with Blimp1 to negatively regulate the expression of
anti-osteoclastogenic genes such as V-maf musculoaponeurotic fibrosarcoma oncogene homolog B
(Mafb), consistent with the increased bone mass and decreased osteoclast number in mice lacking
SIRT6 in hematopoietic cells [112]. Conversely, retroviral-mediated overexpression of SIRT6 increases
osteoclast formation [112]. Thus, SIRT6 regulates osteoclast differentiation, but the extent to which
SIRT6-driven MARylation affects osteoclastogenesis is unclear given the deacetylase activity of this
enzyme (Figure 2).
3. Osteoblast Differentiation
The osteoblasts differentiate from MSCs when exposed to growth factors such as bone
morphogenetic proteins (BMPs), Wnts, Hedgehog, and Notch, which activate transcription factors such
as RUNX2, osterix (OSX), and β-catenin [113]. Unlike osteoclastogenesis, osteoblast differentiation
and function are regulated negatively by inflammatory signals, some of which are mediated by
ARTs [114,115].
3.1. Role of ARTD1 in Osteoblast Differentiation
Immunohistochemical analysis of human bone samples shows that ARTD1 is mostly expressed
in osteoblasts in the areas of new bone formation, to a lesser extent in osteoclasts, while no
positive staining is detected in osteocytes, suggesting a role for ARTD1 in bone formation [116].
Poly-ADP-ribose (PAR) motifs are unexpectedly detected by nuclear magnetic resonance (NMR) and
immunostaining in the bone extracellular matrix, mostly in the calcifying region of the growth plate,
but to a lesser degree in the adjoining nonmineralized hypertrophic cartilage [117]. Thus, PAR units,
which may be released during cell necrosis, are potentially implicated in bone matrix calcification.
Earlier studies using human MSCs and SAOS-2 cells show that during osteoblast differentiation,
hydrogen peroxide activates ARTD1 and promotes osteoblastogenesis via activation of the p38 MAPK
pathway [118–120]. Consistent with its bone anabolic actions, the recruitment of ARTD1 by the long
non-encoding RNA (lncRNA) STEEL results in increased angiogenesis and fracture healing [121].
Furthermore, the ARTD inhibitor PJ34 suppresses osteogenic differentiation of murine MSCs, but
does not affect chondrocyte or adipocyte differentiation [122]. Thus, ARTD1 promotes osteoblast
differentiation under physiological conditions. However, ARTD1 also interacts with NF-κB in mediating
TNF-induced suppression of phosphate-regulating gene with homologies to endopeptidases on the
X chromosome (Phex), whose important functions in bone mineralization include the inhibition of
the expression of the hypophosphatemic fibroblast growth factor 23 (FGF23) [123,124]. Thus, while
ARTD1 favors osteogenesis in homeostatic conditions (Figure 3), it may compromise this process in
inflammatory states.
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Figure 3. Effects of ADP-ribosylation on osteobast formation. ARTD1, ARTD5, and ARTD6 catalyze the
attachment of ADP-ribose polymers from NAD+ to target proteins (PARylation), releasing nicotinamide
(NAM) in the process; their activities promote osteoblast differentiation. SIRT6 promotes osteoblast
development; however the effects of MARylation driven by SIRT6 in this process are not clear because
this enzyme also has deacetylase activity. Lysine deacetylation is coupled to NAD+ hydrolysis, yielding
a deacetylated targeted protein, O-acetyl-ADP-ribose, and NAM. Ac, acetyl.
3.2. Role of ARTD5 and ARTD6 in Osteoblast Differentiation
ARTD5 and ARTD6 PARylate and destabilize AXIN, a negative regulator of the critical
osteogenic Wnt/β-catenin signaling pathway [125]. Bone formation is impaired both in vivo and
in vitro in Sh3bp2-deficient cells through mechanisms involving the tyrosine kinase ABL, and the
transcription factors TAZ and RUNX2 [80,126]. The inhibitors of ARTD5 and ARTD6 enhance in vitro
osteoblastogenesis as the result of accumulated SH3BP2, promote nuclear translocation of ABL, TAZ,
and RUNX2, but they paradoxically decrease bone mass in mice associated with an increased number
of osteoclasts [81]. Thus, by stabilizing AXIN and SH3BP2, the inhibitors of ARTD5 and ARTD6 have
the potential of inhibiting osteogenesis (Figure 3) and inflicting substantial damage to the skeleton.
3.3. Role of SIRT6 in Osteoblast Differentiation
SIRT6-deficient mice exhibit stunted growth as a result of abnormal development of the growth
plate and impaired bone formation [108–110,127]. This phenotype is consistent with the plethoric actions
of this enzyme. Indeed, SIRT6 regulates the expression of RUNX2 and OSX through deacetylation of
H3K9; its deficiency is associated with hyperacetylation of H3K9 at the promoter of dickkopf-related
protein 1 (Dkk1), a potent negative regulator of osteoblastogenesis [110]. SIRT6 also modulates
the expression of the components of BMP signaling, actions that are p300/CBP-associated factor
(PCAF)-dependent [128]. Finally, SIRT6 promotes osteogenic differentiation of rat bone marrow
MSCs partially via suppression of NF-κB [129]. Thus, the actions of SIRT6 are pro-osteogenic
osteoblastogenesis. However, given the importance of protein deacetylation in osteogenesis, a function
that is also carried out by SIRT6, the role of MARylation mediated by this enzyme in this process
is unclear.
4. Adipocyte Differentiation
Bone marrow adiposity and visceral fat are implicated in the pathogenesis of bone diseases
such as osteoporosis [130,131]. Excessive differentiation of MSCs towards adipocytes in conjunction
with the secretion of adipokines (e.g., adiponectin) and cytokines (e.g., IL-6) adversely impact bone
metabolism. The adipogenic differentiation program of MSCs is controlled by transcription factors
such as CCAAT/enhancer binding protein α (C/EBPα) and peroxisome proliferator-activated receptor
γ (PPARγ) [132,133].
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Role of ARTD1 in Adipocyte Differentiation
ARTD1 activity drops for several hours during the early phase of preadipocytes 3T3-L1 cell
differentiation into adipocytes before returning to baseline levels and subsequently reaching higher
levels, presumably as a result of chromatin modifications [134]. Studies using stromal cells from
the fat pads of ARTD1-deficient mice show that the loss of this enzyme is associated with impaired
adipocyte function and differentiation [135]. Accordingly, when fed with a high-fat diet, Artd1 mice
develop hepatosteatosis and dysregulated glucose metabolism. Using the preadipocyte 3T3-L1 cells,
this group further demonstrates that ARTD1 is recruited to the promoters of PPARγ2 and its target
genes such as CD36 and aP2 in a PAR-dependent manner, responses that correlate with decreased
histone marks of repressed chromatin (H3K9me3), while marks of active chromatin (H3K4me3) are
increased [136]. However, studies based on a different mouse line suggest that lack of ARTD1 increases
energy expenditure through SIRT1 activation [137], findings that are consistent with the browning of
primary white adipocytes in vitro by olaparib, an inhibitor of ARTD1 and ARTD2 [138]. Other studies
also show that ARTD1 PARylates C/EBPβ, thereby inhibiting its DNA binding and transcriptional
activities, and ultimately, adipogenesis [139]. Thus, ARTD1 plays various roles in the differentiation of
adipocytes, acting at different stages to promote or inhibit this process.
5. Therapeutic Implications
ARTs are novel and promising targets for cancer therapies. Numerous studies have shown that
various small-molecule inhibitors of ARTDs are efficacious against various cancers, including ovarian
cancer, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular carcinoma, osteosarcoma,
and chordoma [140–151]. More importantly, the US Food and Drug Administration has approved
three different ARTD inhibitors, olaparib, niraparib, and rucaparib for the treatment of BRCA1- or
BRAC2-mutated ovarian cancers. Considering the crucial role that ARTDs play in the pathogenesis
of acute tissue injury or periodontitis, some of these drugs may be indicated for the treatment of
inflammatory osteolysis. However, pre-clinical evidence indicates that genetic or pharmacological
inhibition of ARTD1 or ARTD5 and ARTD6 causes bone loss, a high-risk factor for fracture. Therefore,
comprehensive translational studies may help understand the extent to which ARTD inhibitors may
adversely affect the skeleton.
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